William Lis
Known title: See RemarksCIK: 0001574558
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Transaction History
| ZLAB | ▼ Sell | Open Market | 8,506 | $213K | 8/12/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 7,040 | $127K | 6/22/2026 | View on chart |
| ZLAB | ▲ Buy | Grant | 22,371 | $0 | 6/17/2026 | View on chart |
| ZLAB | ▼ Sell | Open Market | 13,814 | $493K | 6/20/2025 | View on chart |
| ZLAB | ▲ Buy | Grant | 10,831 | $0 | 6/18/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 15,000 | $495K | 2/28/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 10,297 | $178K | 7/1/2024 | View on chart |
| ZLAB | ▼ Sell | Open Market | 100 | $2K | 7/1/2024 | View on chart |
| ZLAB | ▲ Buy | Grant | 21,253 | $0 | 6/18/2024 | View on chart |
| JSPR | ▼ Sell | Open Market | 7,965 | $7K | 10/13/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 18,903 | $500K | 6/29/2023 | View on chart |
| JSPR | ▼ Sell | Open Market | 8,500 | $12K | 4/13/2023 | View on chart |
| ZLAB | ▼ Sell | Open Market | 5,434 | $208K | 3/3/2023 | View on chart |
| JSPR | ▲ Buy | Grant | 29,500 | $0 | 10/12/2022 | View on chart |
| JSPR | ▼ Sell | Open Market | 24,743 | $51K | 6/27/2022 | View on chart |
| JSPR | ▼ Sell | Open Market | 24,743 | $50K | 6/24/2022 | View on chart |
| JSPR | ▲ Buy | Grant | 89,972 | $0 | 3/21/2022 | View on chart |
| ZLAB | ▼ Sell | Open Market | 1,926 | $103K | 1/20/2022 | View on chart |
| ZLAB | ▲ Buy | Grant | 7,763 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.